All stocks / ATXI
AVENUE THERAPEUTICS, INC. ATXI
Avenue Therapeutics (ATXI): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- AVENUE THERAPEUTICS INC
- Market tier
- OTC Pink Current
- Trading status
- Active
- Last trade
- Nov 16
News headlines
The financial report, and what it means
Annual figures to 2025-12-31- Revenue
- $1,404,000
- Net loss
- ($2,909,000)
It spends more than it earns
Under strainCustomers paid it $1.4 million in the year. It lost $2.9 million. For every $1 that came in, about $3.07 went out.
- Cash and cash equivalents
- $2,855,000
- Net cash used in operating activities
- ($1,833,000)
It has cash for a while
SteadyIt had $2.9 million in the bank and used about $152,750 a month. At that pace the money lasts about 19 months unless it borrows or sells more shares.
- Total assets
- $2,931,000
- Total liabilities
- $1,099,000
It owns more than it owes
SteadyEverything the company owns adds up to $2.9 million. Its debts and unpaid bills add up to $1.1 million. That is about $0.37 owed for every $1 owned.
What this adds up to
1 of 3 checks show strain. It spends more than it earns. These are facts from the company's own reports, not a recommendation.
Signals
Estimated float about 2,855,234 shares as of 2026-11-04: 3,294,967 outstanding minus 439,733 held by 1 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
Common questions about ATXI
Does ATXI file reports with the SEC?
Yes. Avenue Therapeutics files with the SEC under company number 0001644963. The most recent filing we hold is a 10-Q dated 2026-11-06.
Source recordHow many ATXI shares are outstanding?
3,294,967 shares as of 2026-11-04, as reported to the SEC.
Source recordHas ATXI filed reports late?
We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.
Is Avenue Therapeutics making money?
Customers paid it $1.4 million in the year. It lost $2.9 million. For every $1 that came in, about $3.07 went out. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)
Source record